VRTX stock slips nearly 5% as concerns over new drug uptake and pipeline setbacks weigh, even as its dominant CF franchise continues to drive steady growth.
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $451.59, denoting a -2.36% move from the preceding trading day.
Vertex Pharmaceuticals (NASDAQ:VRTX) is set to release its earnings on Monday, May 5, 2025. For those trading based on events, analyzing historical stock behavior around earnings announcements can be ...
Zacks Investment Research on MSN
VRTX stock gains on upbeat interim data from kidney disease drug study
Vertex Pharmaceuticals VRTX announced positive data from an interim analysis of the ongoing phase III RAINER study, which ...
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
Fintel on MSN
Maxim Group upgrades Vertex Pharmaceuticals (VRTX)
Fintel reports that on March 18, 2026, Maxim Group upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from Hold to Buy. Analyst Price Forecast Suggests 16.96% Upside As of February 25, ...
Biotechnology companies such as Vertex Pharmaceuticals continue contributing to healthcare representation.
On Monday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported lower-than-expected first-quarter 2025 earnings. Vertex reported first-quarter adjusted earnings per share of $4.06, down from ...
Investors in Vertex Pharmaceuticals, Inc. (Symbol: VRTX) saw new options begin trading today, for the April 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...
Investors in Vertex Pharmaceuticals, Inc. (Symbol: VRTX) saw new options become available today, for the April 25th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results